Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (Q24242258)

5

0 references

Doug Coyle

Doug Coyle

7

0 references

Vivian Welch

Vivian Welch

6

0 references

George Wells

1

George A Wells

0 references

Ann Cranney

2

Ann Cranney

0 references

author name string

Joan Peterson

3

0 references

Michel Boucher

Cochrane Database of Systematic Reviews

4

0 references

publication date

23 January 2008

0 references

published in

0 references

cites work

Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Alendronate in the prevention of osteoporosis: 7-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

What predicts early fracture or bone loss on bisphosphonate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of two forms of alendronate administration upon bone mass after two years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Sustained response to intravenous alendronate in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

An assessment tool for predicting fracture risk in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Mortality following fractures in older women. The study of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

The statistical basis of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Preclinical pharmacology of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Should meta-analysts search Embase in addition to Medline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effects of a combined alendronate and calcitriol agent (Maxmarvil®) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Risk of Mortality Following Clinical Fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

The diagnosis of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Alendronate prevents bone loss in Chinese women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Effects of alendronate on osteopenic postmenopausal Chinese women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Epidemiology of vertebral fractures in women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Population-based study of survival after osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

Alendronate increases bone density and bone strength at the distal radius in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001155.PUB2

7 January 2021

10.1002/14651858.CD001155.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

445257

445257

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference